Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITT Followed by Lomustine for Recurrent Glioblastoma
NCT07145112Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lomustine in glioblastoma (GBM), sponsored by University of California, Davis. Primary endpoints: Safety of LITT + lomustine at 6 weeks and Tolerability of LITT + lomustine at 7 days. Started Oct 2025; status: recruiting.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07145112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145112.